Novavax Inc. [NASDAQ: NVAX] surged by $2.81 during the normal trading session on Friday and reaching a high of $54.83 during the day while it closed the day at $54.43. The company report on July 13, 2022 that U.S. FDA Grants Emergency Use Authorization for Novavax COVID-19 Vaccine, Adjuvanted for Individuals Aged 18 and Over.
Top 5 Cheap Stocks to Own Right Now
While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.
Sign up here to get your free report now. .
Novavax’ vaccine is the first protein-based COVID-19 vaccine authorized in the U.S.
Immunizations with the Novavax COVID-19 Vaccine, Adjuvanted as a primary series will begin upon product release and once a policy recommendation from the CDC is received.
Novavax Inc. stock has also loss -28.49% of its value over the past 7 days. However, NVAX stock has declined by -6.32% in the 3 months of the year. Over the past six months meanwhile, it has lost -58.35% and lost -61.96% year-on date.
The market cap for NVAX stock reached $4.03 billion, with 76.46 million shares outstanding and 75.90 million shares in the current float. Compared to the average trading volume of 7.14M shares, NVAX reached a trading volume of 13678374 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Hereâ€™s what leading stock market gurus have to say about Novavax Inc. [NVAX]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for NVAX shares is $152.60 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on NVAX stock is a recommendation set at 2.10. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
BofA Securities have made an estimate for Novavax Inc. shares, keeping their opinion on the stock as Underperform, with their previous recommendation back on May 20, 2022. While these analysts kept the previous recommendation, B. Riley Securities dropped their target price from $315 to $265. The new note on the price target was released on February 23, 2022, representing the official price target for Novavax Inc. stock. Previously, the target price had yet another raise to $198, while Jefferies analysts kept a Buy rating on NVAX stock.
The Average True Range (ATR) for Novavax Inc. is set at 7.33, with the Price to Sales ratio for NVAX stock in the period of the last 12 months amounting to 2.87. The Price to Book ratio for the last quarter was 64.04.
NVAX stock trade performance evaluation
Novavax Inc. [NVAX] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -28.49. With this latest performance, NVAX shares gained by 40.61% in over the last four-week period, additionally sinking by -58.35% over the last 6 months â€“ not to mention a drop of -69.39% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for NVAX stock in for the last two-week period is set at 48.03, with the RSI for the last a single of trading hit 44.33, and the three-weeks RSI is set at 49.06 for Novavax Inc. [NVAX]. The present Moving Average for the last 50 days of trading for this stock 52.54, while it was recorded at 62.58 for the last single week of trading, and 104.74 for the last 200 days.
Novavax Inc. [NVAX]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Novavax Inc. [NVAX] shares currently have an operating margin of -147.13 and a Gross Margin at +98.90. Novavax Inc.â€™s Net Margin is presently recorded at -152.12.
Return on Equity for this stock declined to -1,265.72, with Return on Assets sitting at -83.85.
Novavax Inc.â€™s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.00 and a Current Ratio set at 1.00.
Earnings per share (EPS) analysis for Novavax Inc. [NVAX] stock
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for NVAX. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Novavax Inc. go to 0.00%.
Novavax Inc. [NVAX]: Insider Ownership positions
There are presently around $1,821 million, or 43.70% of NVAX stock, in the hands of institutional investors. The top three institutional holders of NVAX stocks are: VANGUARD GROUP INC with ownership of 6,966,943, which is approximately 1.014% of the companyâ€™s market cap and around 0.20% of the total institutional ownership; BLACKROCK INC., holding 4,515,805 shares of the stock with an approximate value of $245.79 million in NVAX stocks shares; and STATE STREET CORP, currently with $135.83 million in NVAX stock with ownership of nearly 31.398% of the companyâ€™s market capitalization.
Positions in Novavax Inc. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 212 institutional holders increased their position in Novavax Inc. [NASDAQ:NVAX] by around 6,199,898 shares. Additionally, 204 investors decreased positions by around 6,101,762 shares, while 69 investors held positions by with 21,160,821 shares. The mentioned changes placed institutional holdings at 33,462,481 shares, according to the latest SEC report filing. NVAX stock had 68 new institutional investments in for a total of 2,308,135 shares, while 104 institutional investors sold positions of 844,908 shares during the same period.